Scholarlink

Purpose and Methods <p>The availability of high-concentration 20% subcutaneous immunoglobulin (SCIG 20%) and hyaluronidase-facilitated subcutaneous immunoglobulin 10% (fSCIG 10%) has recently expanded therapeutic options for immunoglobulin replacement therapy in patients with secondary immunodeficiency (SID). The present study aimed to confirm the effectiveness and tolerability of each SCIG formulation in eight patients with SID switched from SCIG 20% to fSCIG 10% and to inform SCIG selection in clinical practice.</p> Results <p>The number of infection events varied among patients and was generally low during each SCIG administration. At the individual patient level, no significant difference was observed in infection rates between SCIG 20% and fSCIG 10%. Local adverse events occurred more frequently with fSCIG 10% than with SCIG 20%. Local adverse events with fSCIG 10% persisted as treatment continued but remained mild.</p> Conclusion <p>These results suggest that dosing interval preferences, adverse event tolerability, and shared decision-making are important considerations in SCIG selection.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effectiveness and tolerability of switching from 20% subcutaneous immunoglobulin to hyaluronidase-facilitated subcutaneous immunoglobulin 10% in the same patients with secondary hypogammaglobulinemia

  • 期刊论文

  • 发表日期：

    2026年5月20日

查看全文
  • Yoshinori Hashimoto,
  • Saaya Hosoda,
  • Hiromi Omura,
  • Takayuki Tanaka

摘要

Purpose and Methods

The availability of high-concentration 20% subcutaneous immunoglobulin (SCIG 20%) and hyaluronidase-facilitated subcutaneous immunoglobulin 10% (fSCIG 10%) has recently expanded therapeutic options for immunoglobulin replacement therapy in patients with secondary immunodeficiency (SID). The present study aimed to confirm the effectiveness and tolerability of each SCIG formulation in eight patients with SID switched from SCIG 20% to fSCIG 10% and to inform SCIG selection in clinical practice.

Results

The number of infection events varied among patients and was generally low during each SCIG administration. At the individual patient level, no significant difference was observed in infection rates between SCIG 20% and fSCIG 10%. Local adverse events occurred more frequently with fSCIG 10% than with SCIG 20%. Local adverse events with fSCIG 10% persisted as treatment continued but remained mild.

Conclusion

These results suggest that dosing interval preferences, adverse event tolerability, and shared decision-making are important considerations in SCIG selection.